Portfolio company
Tizona Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biopharmaceutical company develops first-in-class cancer immunotherapies and antibody-based treatments for patients with advanced solid tumours.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Ona Therapeutics
This company develops antibody-drug conjugates to treat patients with advanced and metastatic cancers which have become resistant to existing therapies.
Pionyr Immunotherapeutics
This company develops antibody therapeutics that modify the tumor microenvironment to treat cancer patients.
3T Biosciences
The company develops T-cell receptor therapeutics and target identification technologies for oncology patients to treat solid tumours.
Bicara Therapeutics
This biotechnology company develops dual-action biologics to treat patients with solid tumours by targeting the tumour microenvironment.
TORL BioTherapeutics
This biopharmaceutical company develops antibody-drug conjugates and monoclonal antibodies to treat various cancers for patients with unmet medical needs.
Avenzo Therapeutics
This biotechnology company develops oncology therapies targeting solid tumours and metastatic breast cancer for patients with high unmet medical needs.
Actym Therapeutics
This biotechnology company develops bacterial immunotherapies to treat solid tumours and fibrotic diseases for patients with advanced cancers.
Arch Oncology
This biotechnology firm develops antibody therapies to treat patients with solid tumours and hematologic malignancies.